VIRI - Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study

Virios Therapeutics (VIRI) announces the dosing of the first patient in its Phase 2b clinical trial evaluating IMC-1 in patients with pain disorder fibromyalgia.Shares up more than 9% premarket.IMC-1 is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir and celecoxib.The trail is a randomized, double-blind, multi-center, placebo-controlled one, which is expected to enroll about 460 patients aged 18-65.The primary endpoint for the trial will focus on reduction in pain over time, as measured daily by the Numerical Rating Scale (“NRS”) 24-Hour Recall scale via an electronic diary.Secondary endpoints will include change in fatigue, sleep disturbance, global health status, and patient function.

For further details see:

Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study